Stocktoria
Liminatus Pharma, Inc. LIMN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-05-18
Liminatus Pharma, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| R&D expense | — | $2.7M |
| Operating income | -$3.0M | -$3.3M |
| Net income | -$10.2M | -$3.5M |
| EPS (diluted) | $-0.43 | $-0.20 |
| Operating cash flow | -$10.0M | -$1.5M |
| Free cash flow | -$10.0M | — |
| Total assets | $512,795 | $5.4M |
| Total liabilities | $10.3M | $24.7M |
| Shareholders' equity | -$9.8M | -$19.3M |
Source: SEC EDGAR filings · CIK 0001971387 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.